Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device may help colorectal cancer patients avoid a temporary colostomy

NCT ID NCT05180565

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device called Colovac+ in 27 adults having surgery for colorectal cancer. The device is placed inside the bowel to protect the surgical connection and keep stool away while it heals. The goal was to see if it is safe and effective, and whether it could help patients avoid needing a temporary colostomy bag.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Dec 2019

Finished

Mar 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (18 years of age or older) * Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for malignancy, based on multidisciplinary team recommendations. * Willingness to comply with Clinical Investigation Plan-specific treatment and study visits and to sign a written Informed Consent Form Exclusion Criteria: \- Preoperatively : 1. Patient with inflammatory bowel disease 2. Known allergy to nickel or other components of the Colovac+ kit 3. Pregnant or nursing female subject 4. Concomitant major surgical procedure in combination with Colorectal resection (i.e. hepatectomy) 5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo Clinical Investigation Plan described procedures or interfere with the interpretation of study results. including, but not limited to: 1. COVID-19 positive (active infection) based on test within 72 hours prior to surgery 2. Metastatic disease - unless previously treated with chemotherapy and resection, and the benefit of exposure to the Colovac device is greater than the risk 1 3. Immunodeficiency (CD4+ count \< 500 CU MM) 4. Systemic steroid therapy within the past 6 months 5. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery 6. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study 7. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis 8. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging 9. Severe Malnutrition defined as 10% weight loss within 3 months prior to enrollment. 6. The subject is currently participating in another investigational drug or device study * Intraoperatively : 7. Anastomosis placement at more than 10cm from anal margin 8. Occurrence of any of the following during the colorectal surgery: 1. Blood loss (\>750 cc) 2. Blood transfusion 3. Any new sign of ischemia 4. Positive air leak test - requiring re intervention on the anastomosis 5. Inadequate bowel preparation 6. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anastomosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHRU Strasbourg

    Strasbourg, 67000, France

  • CHU Lille

    Lille, 59000, France

  • Centre Hospitalier Universitaire St Pierre

    Brussels, 1000, Belgium

  • Hôpital Saint Antoine Paris

    Paris, 75012, France

  • Hôpital Saint Louis

    Paris, 75010, France

  • ICM Montpellier

    Montpellier, 34090, France

  • UZA

    Antwerp, 2610, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.